Thank you, Matt. Good afternoon, everyone, and thank you all for joining us today. I'd also like to thank our faculty, staff and students for their ongoing hard work and commitment. During the third quarter, we continued to execute on our growth and diversification initiatives as we further optimize and scale our company infrastructure. Our results for the quarter exceeded expectations, as we delivered $153.3 million in revenue, $11.4 million in adjusted EBITDA and 5,300 total new student starts across both divisions. As a result of our strong performance in the quarter and year-to-date, we have raised and adjusted our financial guidance, which I'll cover in a few minutes. Significantly, we achieved same-store start growth at our UTI campuses for the first time since the third quarter of 2022 after driving steady improvements in this metric over the past several quarters. We expect this to carry into the fourth quarter, and we're pleased with the progress on this front. Our Q3 performance is a testament to the strength and dexterity of our operating model. I'd like to thank our Concorde and UTI divisional leadership teams, led by Jami Frazier and Tracy Lorenz, respectively, for driving our operational initiatives and enabling us to optimally prepare and position our students for fulfilling careers in the in-demand fields we serve. I'd now like to provide some quick divisional updates for the third quarter, starting with Concorde. We've made great progress with our integration activities, which, to date, have focused on meeting critical public company requirements. Concorde starts have continued to perform well, with strong core program starts in the quarter and across both clinical and core programs in July. To further benefit this performance, we began implementing targeted grant assistance initiatives for certain Concorde students. In contrast to the enhanced grants aimed towards relocating students in our UTI division, our Concorde measures have focused on local students with prior health care experience due to the local nature of Concorde's student body. Though macroeconomic pressures have historically had less impact on Concorde's current students and prospects, having this enhanced support for specific programs and campuses has helped our incoming health care students. From program and growth perspective, Concorde is currently planning to launch six new programs, which could begin as soon as September, with the remainder launching in fiscal 2024. These rollouts include three new dental hygiene programs we previously mentioned, which remain on track to launch next year. The other three programs are smaller programs that we more recently identified as opportunities. They already have Department of Education approval and of relatively low investment and ramp-up requirements, thus, we made the decision to launch them at two campuses in the coming months. The first of these programs, which consists of the diagnostic medical and cardiovascular sonography programs or DMS and CVS, respectively, could begin starting students in September. Moving to the UTI division. We continued to execute on our two main 2023 growth drivers for this segment, new program launches and the scaling of our two newest campuses in Austin, Texas and Miramar, Florida. Starting with UTI's program rollouts, we're now entering the launch phase for 14 new programs across nine UTI campuses planned for this fiscal year. These programs, which include wind and energy management, aviation, robotics and HVAC/R, primarily came to UTI by the way of MIAT acquisition as we continue to extract value from that investment. In July, we launched the first tranche of programs at four campuses. Combined, these programs started their initial cohorts with approximately 70 students, which represents an encouraging start performance in these early days. Between August and September, UTI expects to launch the remaining planned new programs across six campuses. In fact, two campuses launched robotics programs just yesterday. We received the final FAA approval needed for the Avondale aviation program in early July. We expect to receive two other outstanding aviation program approvals in September. Other than the two final aviation approvals, we have worked through the industry-wide regulatory approval delays UTI experienced earlier this year, which compressed the program launch time lines and caused us to shift a few start dates to later in the quarter than originally planned. Overall, demand for the new programs has remained strong as we further ramp our marketing efforts. Our preliminary fiscal 2023 guidance included modest benefits on student starts and revenue for the planned program launches, and we expect further benefits and higher growth expectations from these launches in fiscal 2024 and onward. Turning to Austin and Miramar, UTI's two newest campuses, continue to scale nicely with over 800 students combined. These campuses were also designed with program expansion areas, and they will house some of our new programs, which began with the July launch of HVAC/R at Austin and aviation in Miramar is targeted for September. Our progress on both campuses remains on track to meet or exceed expectations, and we will maintain our work on scaling and identifying future expansion initiatives. Broader UTI divisional enrollment patterns have been moving in the right direction and overall demand and entry volumes remain high. We're very pleased to report overall start growth for the UTI division of 5%. And with that, a few points of same-store growth during the quarter. This was largely driven by continued gains with local students and improved traction with relocating students to whom UTI provided targeted support package enhancements during the quarter. These efforts complement the initiatives the team has previously implemented to mitigate inflation-related pressure on relocating students across the UTI channel. The UTI division will keep assisting these groups through dedicated support and financial aid teams, along with varying the mix of grant enhancements as needed. This comes in conjunction with working to further ramp the yield of our division's admissions and marketing investments to support high school and military channel recruitment, which are traditionally less affected by inflation. Our work across both divisions reflects our core commitment to driving positive student outcomes. This commitment and the reputation we've built over nearly 60 years of operation has given us an industry leadership position that we're dedicated to maintaining. Example, our Concorde campuses in Orlando and San Antonio, along with our UTI campus in Exton, Pennsylvania, were all recently recognized as our latest ACCSC Schools of Excellence award winner. Our UTI campus in Long Beach, California was also recognized as an ACCSC School of Distinction. This award recognizes ACC-accredited schools for their commitment to the expectations and rigors of ACCSC accreditation as well as demonstrating exceptional student achievement. We have a long history of receiving these designations across our campus footprint, and we're honored to receive these most recent recognitions. We will continue to uphold the quality of our instruction, industry partnerships and career preparation across health care, transportation and skilled trades. As Troy will discuss in more detail later in the call, with our strong performance through the first 3 quarters and visibility we have into the fourth quarter, we've tightened our expected revenue guidance range and raised our adjusted EBITDA range for fiscal 2023. We now expect fiscal year 2023 revenue to range between $602 million and $605 million. As for adjusted EBITDA, we now expect the range to be $62 million to $64 million. We are reiterating and tracking comfortably towards the middle of our expected fiscal year 2023 new student start range of between 22,000 and 23,500, and we remain confident in our previously stated fiscal 2024 projections of exceeding $700 million in annual revenue and approaching $100 million in adjusted EBITDA. We'll provide formal guidance ranges for 2024 when we report our year-end results in just a few months. I'm proud of the strategic progress and execution we've maintained across both segments year-to-date. I'd now like to turn the call over to Troy to discuss our results from the quarter in more detail. Troy?